Literature DB >> 30868387

Added value of diffusion-weighted MRI for nodal radiotherapy planning in pelvic malignancies.

N Sushentsev1, H Martin2, Y Rimmer2, T Barrett3,4.   

Abstract

PURPOSE: To evaluate the added value of diffusion-weighted imaging (DWI) to T2-weighted imaging (T2WI) for improved identification of pelvic lymph nodes (LN) by radiation oncologists. METHODS/PATIENTS: This retrospective study included 20 patients with histopathologically proven node-negative prostate cancer. All patients underwent 3T-MRI of the prostate; matched axial T2WI and DWI sequences were assessed by an experienced uro-radiologist as the reference standard. Consultant and specialist registrar radiation oncologists were asked to identify all LN first on T2WI alone (read 1) and then on T2WI and DWI combined (read 2); LN were measured in size and divided into true positives (TP), false positives (FP) and false negatives (FN). Sensitivity, positive predictive value (PPV) and false negative rate (FNR) were then calculated and compared using Pearson's Chi square test.
RESULTS: A total of 177 LN comprised the reference standard. 16 TP, 16 FP and 161 FN LN (sensitivity 9.0%, PPV 50.0%, FNR 91.0%) and 124, 15 and 53 LN (70.1%, 89.2%, 30%) were identified by reader 1 on reads 1 and 2, respectively; χ2 (2, N = 385) = 137.8, p < 0.0001. 27, 21 and 150 LN (15.3%, 56.3%, 84.8%) and 120, 13 and 57 LN (67.8%, 90.2%, 32.2%) were identified by reader 2 on the two reads; χ2 (2, N = 388) = 102.4, p < 0.0001.
CONCLUSIONS: Adding DWI to T2WI significantly improved identification of pelvic LN by radiation oncologists and can therefore be regarded as a useful LN contouring technique for RT planning in pelvic malignancies.

Entities:  

Keywords:  Diffusion-weighted imaging; Lymph nodes; MRI; Pelvic malignancies; Prostate cancer; Radiotherapy planning

Mesh:

Year:  2019        PMID: 30868387     DOI: 10.1007/s12094-019-02068-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  27 in total

1.  What is the pelvic lymph node normal size? Determination from normal MRI examinations.

Authors:  Marjorie Ramirez; Pierre Ingrand; Jean-Pierre Richer; Guillaume Herpe; Guillaume Vesselle; Samy Boucebci; Jean-Pierre Tasu
Journal:  Surg Radiol Anat       Date:  2015-10-29       Impact factor: 1.246

2.  An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition.

Authors:  A Taylor; A G Rockall; M E B Powell
Journal:  Clin Oncol (R Coll Radiol)       Date:  2007-07-10       Impact factor: 4.126

3.  Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  B Glimelius; E Tiret; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

4.  Evaluating the effect of rectal distension on prostate multiparametric MRI image quality.

Authors:  Iztok Caglic; Nienke L Hansen; Rhys A Slough; Andrew J Patterson; Tristan Barrett
Journal:  Eur J Radiol       Date:  2017-02-22       Impact factor: 3.528

5.  Twenty Fraction Prostate Radiotherapy with Intra-prostatic Boost: Results of a Pilot Study.

Authors:  E Onjukka; J Uzan; C Baker; L Howard; A Nahum; I Syndikus
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-09-29       Impact factor: 4.126

6.  Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma.

Authors:  David K Gaffney; Bronwyn King; Akila N Viswanathan; Maroie Barkati; Sushil Beriwal; Patricia Eifel; Beth Erickson; Anthony Fyles; Jennifer Goulart; Matthew Harkenrider; Anuja Jhingran; Ann Klopp; Wui-Jin Koh; Karen Lim; Ivy Petersen; Lorraine Portelance; William Small; Alexandra Stewart; Ericka Wiebe; Aaron Wolfson; Catheryn Yashar; Walter Bosch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-21       Impact factor: 7.038

7.  Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging.

Authors:  Robert Dinniwell; Philip Chan; Gregory Czarnota; Masoom A Haider; Kartik Jhaveri; Michael Jewett; Anthony Fyles; David Jaffray; Michael Milosevic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-12-25       Impact factor: 7.038

8.  Validation of 3 T MRI including diffusion-weighted imaging for nodal staging of newly diagnosed intermediate- and high-risk prostate cancer.

Authors:  C von Below; G Daouacher; C Wassberg; R Grzegorek; C Gestblom; J Sörensen; H Ahlström; M Waldén
Journal:  Clin Radiol       Date:  2016-01-13       Impact factor: 2.350

9.  A verification study of proposed pelvic lymph node localisation guidelines using nanoparticle-enhanced magnetic resonance imaging.

Authors:  Maria J Vilarino-Varela; Alexandra Taylor; Andrea G Rockall; Rodney H Reznek; Melanie E B Powell
Journal:  Radiother Oncol       Date:  2008-09-02       Impact factor: 6.280

Review 10.  Intensity-modulated radiotherapy for prostate cancer.

Authors:  Ben W Fischer-Valuck; Yuan James Rao; Jeff M Michalski
Journal:  Transl Androl Urol       Date:  2018-06
View more
  1 in total

1.  Multiparametric MRI - local staging of prostate cancer and beyond.

Authors:  Iztok Caglic; Viljem Kovac; Tristan Barrett
Journal:  Radiol Oncol       Date:  2019-05-08       Impact factor: 2.991

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.